Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00792701 · ClinicalTrials.gov registry record · Phase 2
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 20
- Study locations
NCT00792701: Completed Phase 2 study of Lung Cancer, sponsored by SWOG Cancer Research Network.
NCT00792701 is a Phase 2 study of Lung Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 85 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00792701, a Phase 2 study of Lung Cancer, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy drugs after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. PURPOSE: This phase II trial is studying how well giving gemcitabine together with cisplatin works in treating patients with stage I non-small cell lung cancer that was removed by surgery.
Primary Outcome
Feasibility will be assessed both by accrual rate and the percentage of patients successfully assigned to adjuvant chemotherapy or active monitoring.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG gemcitabine hydrochloride
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- Tibotec Therapeutics - Division of Ortho Biotech Products, LP - Marysville
- Valley Medical Oncology Consultants - Pleasanton - Pleasanton
- Sutter Cancer Center at Roseville Medical Center - Roseville
- Sutter Cancer Center - Sacramento
- University of California Davis Cancer Center - Sacramento
- Tahoe Forest Cancer Center - Truckee
Illinois
- Saint Anthony's Hospital at Saint Anthony's Health Center - Alton
- Decatur Memorial Hospital Cancer Care Institute - Decatur
- Sherman Hospital - Elgin
- Regional Cancer Center at Memorial Medical Center - Springfield
Kansas
- Cancer Center of Kansas, PA - Chanute - Chanute
- Cancer Center of Kansas, PA - Dodge City - Dodge City
- Cancer Center of Kansas, PA - El Dorado - El Dorado
- Cancer Center of Kansas - Fort Scott - Fort Scott
Arkansas
- Hembree Mercy Cancer Center at St. Edward Mercy Medical Center - Fort Smith
Connecticut
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center - Hartford
Georgia
- Northeast Georgia Medical Center - Gainesville
Hawaii
- Tripler Army Medical Center - Honolulu
Indiana
- St. Francis Hospital and Health Centers - Beech Grove Campus - Beech Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2008-11 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
What the finished NCT00792701 record still lists
NCT00792701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which cisplatin is the first listed.
NCT00792701 names 20 study sites across 8 states, led by California, Illinois, Kansas.
Frequently Asked Questions
What is clinical trial NCT00792701 about?
NCT00792701 is a clinical study titled "S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy drugs after surgery may kill any tumor cells that remain after surgery. Sometimes, af...
What is the current status of trial NCT00792701?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2008-11. Estimated completion is 2016-04.
What conditions does trial NCT00792701 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00792701?
The interventions under investigation include: cisplatin (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00792701?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00792701 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00792701's enrollment target sits among peer trials
85 209th of 409 higher than 200 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia